IBPM 002BZ
Alternative Names: IBPM002BZ; IBPM002BZ (biosimilar) - Inbiopro SolutionsLatest Information Update: 04 Nov 2017
At a glance
- Originator Inbiopro Solutions
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Renal cell carcinoma; Small cell lung cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer(Metastatic disease) in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Renal-cell-carcinoma(Metastatic disease) in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Small-cell-lung-cancer in India (Parenteral)